Aurora Cannabis (TSX:ACB) and Aphria (TSX:APHA) Get a Leg Up on the Competition

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB), and Aphria Inc. (TSX:APHA)(NYSE:APHA) were big winners in Germany. They now have a leg up in Europe.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Fort the most part, marijuana stocks have been bid up for one reason: the legalization of recreational marijuana in Canada. Pot stocks have sky-high valuations, and at the moment, their success as investments is dependent on this recreational demand.

Lost amid the recreational hype is medical marijuana. Most pot stocks got their start as licensed medical marijuana producers. Major players, such as Canopy Growth, Aurora Cannabis (TSX:ACB)(NYSE:ACB), and Aphria (TSX:APHA)(NYSE:APHA) all had a leg up on the competition thanks to their status as reliable and high-quality medical marijuana producers.

Last week, one of Europe’s biggest markets, Germany, announced the winners of its recent tender for licensed producers and distributors of medical marijuana.

German medical marijuana

On Thursday, the German government announced that three companies had split the 13 lots available. Aurora Cannabis and Aphria were among those three. Although the agreements are subject to a 10-day waiting period, there is no reason to believe these contracts won’t be finalized.

Aurora announced that it was awarded five of the 13 lots — the maximum number any single suppliers could win. Over the course of four years (the duration of the contract), Aurora will supply at minimum 4,000 kg of marijuana.

Aphria was also awarded the maximum number of lots (five). Its minimum capacity is much lower however, at 200 kg annually.

The numbers don’t seem like much, and they aren’t. So, why are these contracts important?

Europe’s largest pot market

For starters, Germany is Europe’s largest medical marijuana market. It is estimated that the market was worth US$78 million in 2018 and is expected to rise to $2.7 billion by 2023. That is a compound annual growth rate of 672%!

Germany is facing significant supply shortages, which was the catalyst to go to tender. Since legalization in 2017, existing suppliers have been unable to keep up with demand. As such, patients have been paying a high price for products.

The minimum supply agreements aren’t significant enough to move the needle. However, it is important to note that these are minimums and they are now key suppliers in a massive growth market. Much like they had positioned themselves in Canada before recreational legalization, they now have a leg up on the competition in Germany.

Likewise, securing agreements with Germany’s government increases their legitimacy as producers. Much like Canada, Germany has very strict regulations. This should enable them to enter other European markets more seamlessly.

Foolish takeaway

Coming out as winners in Germany’s recent tender is a significant catalyst. There were over 79 applications and only three were selected. Not only does it give Aurora and Aphria access to the high-growth German market, it positions them well to execute their European strategies.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »